Efficacy, Safety and Tolerability Study of SHAPE in IA, IB or IIA Cutaneous T-cell Lymphoma
A Randomized Phase 2 Study to Evaluate Three Treatment Regimens of SHAPE, a Histone Deacetylase Inhibitor, in Patients With Stage IA, IB or IIA Cutaneous T-Cell Lymphoma
Sponsor: TetraLogic Pharmaceuticals
Listed as NCT02213861, this PHASE2 trial focuses on Cutaneous T-Cell Lymphoma (CTCL) and remains ongoing. Sponsored by TetraLogic Pharmaceuticals, it has been updated 7 times since 2014, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.
Status Flow
Change History
7 versions recorded-
Sep 2024 — Present [monthly]
Unknown PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Unknown PHASE2
Status: Unknown Status → Unknown
-
Jan 2021 — Jul 2024 [monthly]
Unknown Status PHASE2
-
Nov 2018 — Jan 2021 [monthly]
Unknown Status PHASE2
Status: Active Not Recruiting → Unknown Status
-
Jun 2018 — Nov 2018 [monthly]
Active Not Recruiting PHASE2
▶ Show 2 earlier versions
-
Feb 2017 — Jun 2018 [monthly]
Active Not Recruiting PHASE2
-
Jan 2017 — Feb 2017 [monthly]
Active Not Recruiting PHASE2
First recorded
Nov 2014
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- TetraLogic Pharmaceuticals
For direct contact, visit the study record on ClinicalTrials.gov .